Literature DB >> 6600888

Honey bee venom specific immunoglobulin G4 in honey bee sting allergic patients and bee keepers.

N K Cheung, J Blessing-Moore, M J Reid, G Yang.   

Abstract

Honey bee venom (HBV) IgG4 antibody was studied in bee keepers and honey bee sting allergic patients on immunotherapy using mouse monoclonal anti-human IgG4 antibody in a modified microtiter solid phase radioimmunoassay (MSPIRA). The mean HBV IgG4 in bee keepers was 31 units/ml. In patients the mean HBV IgG4 pre- and post-immunotherapy were 2.9 and 11.6 units/ml, respectively, representing a mean rise of 7.3-fold as compared to a rise of 1.6-fold for total HBV IgG. The mean HBV IgG level in bee keepers was 14 micrograms/ml which was not significantly different from the mean level of 17 micrograms/ml in allergic patients at diagnosis. The percentage interference of HBV IgE detection in vitro correlated with HBV IgG but not with HBV IgG4. On the other hand, there was an inverse relationship between serum HBV IgE and HBV IgG4 levels while none was found for HBV IgE and IgG.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6600888

Source DB:  PubMed          Journal:  Ann Allergy        ISSN: 0003-4738


  4 in total

1.  Aberrant IgG subclass distribution to measles in healthy seropositive individuals, in patients with SSPE and in immunoglobulin-deficient patients.

Authors:  T Mathiesen; L Hammarström; E Fridell; A Linde; G Wirsen; C I Smith; E Norrby; B Wahren
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

2.  Radioimmunoassays for specific human IgG4.

Authors:  N K Cheung
Journal:  Clin Rev Allergy       Date:  1983-06

3.  Disodium cromoglycate (DSCG) selectively inhibits IgE production and enhances IgG4 production by human B cell in vitro.

Authors:  H Kimata; A Yoshida; C Ishioka; H Mikawa
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

4.  Disodium cromoglycate enhances ongoing immunoglobulin production in vitro in human B cells.

Authors:  H Kimata; A Yoshida; C Ishioka; H Mikawa
Journal:  Immunology       Date:  1991-05       Impact factor: 7.397

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.